TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07414836: A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$691,152

Rescue Site Savings

+$471,240

Unlock Full NCT07414836 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07414836 Rescue Dossier →